Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries’ subsidiary Sun Laboratories is planning to hit the domestic bond market in order to raise up to Rs 1,000 crore to fund an internal restructuring. The Mumbai-based drug maker has divided the issue into two parts of Rs 500 crore, one maturing in two years and the other in three years. It is priced in the range of 7.90%-7.96%, 25-35 basis points higher than similar maturity government securities, making the borrowing cost less than any term bank loan.

Sun Pharma is the fifth largest specialty generic pharmaceutical company in the world. The company provides high quality, affordable medicines trusted by healthcare professionals and patients in over 150 countries worldwide.